Seelos Therapeutics’ stock surged after the company announced a partnership with the US Army to test its intranasal ketamine drug, SLS-002, for PTSD in military personnel and veterans. The trial, funded by the Department of Defense, will evaluate the drug’s effectiveness, safety, and tolerability.